Zura Bio Reports Global P-II (TibuSURE) Trial of Tibulizumab to Treat Adults with Systemic Sclerosis
Shots:
- Zura Bio has reported a global P-II (TibuSURE) trial assessing safety, tolerability & efficacy of tibulizumab in adults (n=80) with early diffuse cutaneous systemic sclerosis (dcSSc). It includes 24wks. efficacy period & a 28wks. open-label extension
- The 1EP is the modified Rodnan Skin Score (mRSS), with key efficacy EPs of lung disease (evaluated by qHRCT & FVC), physical function (assessed by HAQ-DI) & revised Combined Response Index in Systemic Sclerosis (rCRISS)
- Tibulizumab is a tetravalent bispecific antibody targeting IL-17A & BAFF formed by combining Taltz (ixekizumab) & tabalumab. It is set to enter P-II for hidradenitis suppurativa in Q2’25
Ref: Zura Bio | Image: Zura Bio
Related News:- Zura Bio to Go Public via JATT SPAC Merger for ~$215M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
